233 related articles for article (PubMed ID: 28983664)
1. [Radiation therapy of locally advanced prostate cancer].
Schmidt-Hegemann NS; Li M; Eze C; Belka C; Ganswindt U
Urologe A; 2017 Nov; 56(11):1402-1409. PubMed ID: 28983664
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
3. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
5. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.
Panje CM; Dal Pra A; Zilli T; R Zwahlen D; Papachristofilou A; Herrera FG; Matzinger O; Plasswilm L; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):778-86. PubMed ID: 25986251
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
7. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
Zumsteg ZS; Zelefsky MJ
Lancet Oncol; 2012 Jun; 13(6):e259-69. PubMed ID: 22652234
[TBL] [Abstract][Full Text] [Related]
10. Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Hayman J; Hole KH; Seierstad T; Perin J; DeWeese TL; Tran PT; Lilleby W
Urol Oncol; 2019 Apr; 37(4):289.e19-289.e26. PubMed ID: 30446451
[TBL] [Abstract][Full Text] [Related]
11. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
12. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
14. Locally advanced prostate cancer: effective treatments, but many adverse effects.
Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
17. Current standards and future directions for prostate cancer radiation therapy.
Pinkawa M; Schoth F; Böhmer D; Hatiboglu G; Sharabi A; Song D; Eble MJ
Expert Rev Anticancer Ther; 2013 Jan; 13(1):75-88. PubMed ID: 23259429
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
Roach M
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
[TBL] [Abstract][Full Text] [Related]
19. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy and androgen deprivation in the management of high risk prostate cancer.
Dal Pra A; Cury FL; Souhami L
Int Braz J Urol; 2011; 37(2):161-75; discussion 176-9. PubMed ID: 21557833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
